Welcome to our dedicated page for Karuna Therapeutics news (Ticker: KRTX), a resource for investors and traders seeking the latest updates and insights on Karuna Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karuna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karuna Therapeutics's position in the market.
Karuna Therapeutics (NASDAQ: KRTX) has announced that its senior management will participate in a fireside chat at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 8:40 a.m. ET. A live webcast of the event will be available on the Investor Relations page of Karuna’s website, with a replay accessible for 30 days post-conference. Karuna is focused on developing transformative medicines for psychiatric and neurological conditions, striving for more effective treatments that can significantly improve patients’ lives.
Karuna Therapeutics (NASDAQ: KRTX) has announced that CEO Steve Paul will participate in a panel discussion titled “Emerging Therapies for Psychiatric Disorders” at the Citi 16th Annual BioPharma Virtual Conference on September 8, 2021, at 10:40 a.m. ET. A live webcast will be available on the Investor Relations page of Karuna’s website, with a replay archived for up to 30 days. As a clinical-stage biopharmaceutical company, Karuna is focused on developing transformative treatments for psychiatric and neurological conditions.
Karuna Therapeutics announced its Q2 2021 financial results, reporting a net loss of $34.4 million, up from $17.0 million year-over-year, primarily due to rising R&D costs. The company is advancing its lead asset KarXT in mid- and late-stage trials for schizophrenia and dementia-related psychosis. All four Phase 3 EMERGENT trials for schizophrenia are currently enrolling, with completion of the first trial expected mid-2022. The company ended Q2 with $543.6 million in cash, ensuring funding for its operations for at least the next 12 months.
Karuna Therapeutics, Inc. (NASDAQ: KRTX) has announced that CEO Steve Paul will join a panel titled “The Brains of the Operation - Novel Approaches in Neuro” at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 12:00 p.m. ET. A live webcast will be available on Karuna’s Investor Relations page, with a replay accessible for 30 days post-conference. Karuna focuses on developing transformative medicines for psychiatric and neurological conditions, aiming for more effective treatments based on advanced neuroscience.
Karuna Therapeutics (NASDAQ: KRTX) announced positive results from its Phase 1b trial of KarXT (xanomeline-trospium) involving healthy elderly volunteers. The trial highlighted the tolerability of KarXT, with over 80% of treatment-related adverse events rated as mild. A single serious adverse event of urinary retention was observed, linked to higher doses of trospium in one cohort. With promising results, the company aims to initiate a Phase 2 trial targeting dementia-related psychosis in the first half of 2022, building on a previous Phase 2 study's findings.
Karuna Therapeutics (NASDAQ: KRTX) has announced its participation in two upcoming virtual investor conferences. The Goldman Sachs 42nd Annual Global Healthcare Conference is scheduled for June 8, 2021, at 1:20 p.m. ET, followed by the JMP Securities Life Sciences Conference on June 17, 2021, at 4:00 p.m. ET. Live webcasts of both presentations will be available on the company’s Investor Relations page, with replays accessible for 30 days post-event. Karuna is focused on developing transformative medicines for psychiatric and neurological conditions.
Karuna Therapeutics (NASDAQ: KRTX) reported a net loss of $30.5 million for Q1 2021, up from $8.7 million in the prior period. Key developments include the initiation of three Phase 3 trials in its EMERGENT program for KarXT, an investigational treatment for schizophrenia. The company completed a successful follow-on offering, raising $270 million. Research and development expenses surged to $20.2 million, up from $4.4 million, reflecting increased clinical trial activities. Karuna ended the quarter with $571.3 million in cash, providing a runway for at least 12 months following potential NDA submission.
Karuna Therapeutics (NASDAQ: KRTX) announced its participation in upcoming virtual investor conferences. The Bank of America 2021 Health Care Conference is scheduled for May 13, 2021, at 9:30 a.m. ET, followed by the RBC Capital Markets 2021 Global Healthcare Conference on May 18, 2021, at 4:50 p.m. ET. Live webcasts will be available on their Investor Relations page, with a replay accessible for 90 days post-conference. Karuna focuses on developing transformative medicines for psychiatric and neurological conditions, leveraging neuroscience knowledge.
Karuna Therapeutics (NASDAQ: KRTX) announced participation in two upcoming virtual investor conferences. The Oppenheimer 31st Annual Healthcare Conference is set for March 16, 2021, at 10:00 a.m. ET, and the Stifel’s 3rd Annual CNS Day will take place on March 31, 2021, at 9:30 a.m. ET. Live webcasts of the presentations will be available on Karuna's Investor Relations page, with replays archived for 90 days. Karuna is focused on developing transformative treatments for psychiatric and neurological conditions.
Karuna Therapeutics (NASDAQ: KRTX) has announced the pricing of an underwritten public offering of 2,083,334 shares at $120.00 each, aiming for gross proceeds of approximately $250 million. The offering includes a 30-day option for underwriters to purchase an additional 312,500 shares. The transaction is expected to close around March 4, 2021, pending customary conditions. The shares are offered under an effective shelf registration statement filed with the SEC, with Goldman Sachs and J.P. Morgan serving as joint book-running managers.